Remove BMI Remove Heart Attack Remove Lipid disorders
article thumbnail

FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity

DAIC

Food and Drug Administration ( FDA ) has approved an additional indication for Wegovy ( semaglutide ) to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along with a reduced calorie diet and increased physical activity.

Obesity 111